PDE1B

Across TCGA pan-cancer cohorts, PDE1B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDE1B data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDE1B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDE1B expression acts as an unfavorable survival marker.

PDAC, LSCC, and LUAD are the cancer types where PDE1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.231	0.639	.002	34	view →
LSCC	DFS	Median	II,III,IV	0.795	1.000	.003	12	view →
LUAD	OS	Median	All	0.567	0.916	.010	5	view →
CCRCC	OS	Median	II,III,IV	0.441	0.891	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDE1B–PDAC (DFS)

Open the PDAC breakdown →